Previous close | 11.23 |
Open | 10.91 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 10.85 - 11.81 |
52-week range | 6.08 - 13.04 |
Volume | |
Avg. volume | 14,488 |
Market cap | 75.315M |
Beta (5Y monthly) | 1.18 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Instil Bio (TIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.
The heavy selling pressure might have exhausted for Instil Bio, Inc. (TIL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.